drugset / Trial / NCT04433078

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

NCT04433078

Phase 2 Withdrawn Temple University
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively. The investigators hypothesize that Doxycycline will will improve survival and reduce morbidity in SARS-CoV-2 infected patients. A secondary aim is to identify genetic variants that predict either an unusually mild disease or an unusually severe disease - knowledge that can be used to design new and precise medications and to be able to predict patients who might get into early trouble and to therefore hospitalize them.

Timeline

Start
2020-06-22
Primary completion
2021-04-13
Completion
2021-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg